DA Davidson Issues Pessimistic Forecast for USANA Health Sciences (NYSE:USNA) Stock Price

USANA Health Sciences (NYSE:USNA) had its price objective cut by equities researchers at DA Davidson from $38.00 to $36.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a “neutral” rating on the stock. DA Davidson’s price target suggests a potential upside of 21.83% from the company’s current price. DA Davidson also issued estimates for USANA Health Sciences’ Q1 2025 earnings at $0.83 EPS, Q1 2025 earnings at $0.76 EPS, Q1 2025 earnings at $0.76 EPS, FY2025 earnings at $2.57 EPS, FY2025 earnings at $2.38 EPS, FY2025 earnings at $2.38 EPS, FY2026 earnings at $2.59 EPS and FY2026 earnings at $2.68 EPS.

Other equities research analysts have also recently issued research reports about the stock. StockNews.com cut shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, February 14th. Sidoti lowered USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 18th.

USANA Health Sciences Price Performance

Shares of USNA opened at $29.55 on Thursday. USANA Health Sciences has a 1 year low of $27.71 and a 1 year high of $50.32. The stock’s fifty day moving average price is $33.50 and its two-hundred day moving average price is $36.56. The firm has a market cap of $563.22 million, a PE ratio of 10.44, a PEG ratio of 0.93 and a beta of 0.87.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.15. The business had revenue of $213.61 million for the quarter, compared to analysts’ expectations of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. Sell-side analysts anticipate that USANA Health Sciences will post 2.45 earnings per share for the current fiscal year.

Institutional Trading of USANA Health Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. R Squared Ltd bought a new position in USANA Health Sciences in the 4th quarter valued at $28,000. Safe Harbor Fiduciary LLC bought a new stake in USANA Health Sciences during the third quarter valued at $30,000. KBC Group NV boosted its stake in USANA Health Sciences by 96.6% during the third quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after buying an additional 519 shares during the period. KLP Kapitalforvaltning AS bought a new position in USANA Health Sciences in the 4th quarter worth about $83,000. Finally, Quantbot Technologies LP purchased a new stake in shares of USANA Health Sciences in the 4th quarter valued at about $132,000. Institutional investors own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.